Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Bladder01: Izalontamab Brengitecan vs Platinum-based Chemotherapy in Metastatic Urothelial Cancer
NCT07106762Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Jan 2029
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 22
01
Overview
A Phase 3 trial of izalontamab brengitecan in urothelial carcinoma (UC), sponsored by Bristol Myers Squibb. Started Sep 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07106762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106762.